ProCE Banner Activity

SKYSCRAPER-02: Phase III Trial of First-line Atezolizumab + Carboplatin/Etoposide ± Tiragolumab, an Anti-TIGIT Antibody, in ES-SCLC

Slideset Download
Conference Coverage
The phase III SKYSCRAPER-02 trial showed no additional benefit with tiragolumab added to first-line atezolizumab plus carboplatin/etoposide in ES-SCLC.

Released: June 09, 2022

Expiration: June 08, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab